Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH Return-On-Investment Report Will Be Subject Of Senate Hearing This Fall

Executive Summary

The Senate Commerce/Science Subcommittee will hold hearings this fall on the return to taxpayers from research funded by the National Institutes of Health.

You may also be interested in...



Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push

NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol

Closing The Books On Taxol: GAO Report Fuels Sen. Wyden’s Pricing Push

NIH should consider the cost of new therapies to Medicare when negotiating technology transfers for taxpayer-funded research, Sen. Ron Wyden (D-Ore.) maintained in response to a June 4 1GAO report on the National Institutes of Health's collaboration with Bristol for the oncologic agent Taxol

NIH-funded research

Senate Commerce/Science Subcommittee Chairman Ron Wyden (R-Ore.) no longer plans hearings or legislation to address the return to taxpayers from research funded by the National Institutes of Health. Wyden met Oct. 10 with reps from NIH, the pharmaceutical industry and research institutions. Wyden is understood to be satisfied by NIH's plan to begin implementation of a web-based database of approved drugs that use technology funded by NIH and to use standardized language to simplify reporting requirements by Jan. 1 (1"The Pink Sheet" Aug. 27, p. 3)

Related Content

UsernamePublicRestriction

Register

PS038408

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel